CIGB 247

Drug Profile

CIGB 247

Alternative Names: Antigen p64K hVEGFKDR adjuvant NAcGM3 VSSP; CIGB 247 V; CIGB-247; CIGB-247-V-vaccine; HeberSaVax vaccine; hVEGFKDR p64K antigen NAcGM3 VSSP adjuvant; hVEGFKDR p64K vaccine; hVEGFKDR- p64K antigen/adjuvant NAcGM3/VSSPs; p64K hVEGFKDR vaccine

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Cancer vaccines; Eye disorder therapies
  • Mechanism of Action Immunostimulants; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours
  • Preclinical Age-related macular degeneration

Most Recent Events

  • 05 Mar 2018 Efficacy and immunogenicity data from phase I/Ib trials presented at 16th International Congress on Targeted Anticancer Therapies
  • 05 Mar 2018 Center for Genetic Engineering and Biotechnology and Heber Biotec plans four phase II/III trial in 2018
  • 06 Jun 2017 Center for Genetic Engineering and Biotechnology plans the CENTAURO-4 phase II/III trial for Ovarian cancer and Fallopian tube cancer (Late-stage disease, Inoperable/Unrescetable) in Cuba (RPCEC00000246)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top